Analysis

Mid-afternoon market update: Dow surges 200 points; Sutro Biopharma shares spike higher

Toward the end of trading Friday, the Dow traded up 0.68% to 30,173.52 while the NASDAQ rose 0.53% to 12,442.66. The S&P also rose, gaining 0.71% to 3,692.88.

The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 14,147,730 cases with around 276,400 deaths. India confirmed a total of at least 9,571,550 confirmed cases and 139,180 deaths, while Brazil reported over 6,487,080 COVID-19 cases with 175,270 deaths. In total, there were at least 65,315,460 cases of COVID-19 worldwide with over 1,508,900 deaths, according to data compiled by Johns Hopkins University.

Leading and Lagging Sectors

Energy shares climbed 5.1% on Friday. Meanwhile, top gainers in the sector included Callon Petroleum Company CPE 25.95%, up 26%, and Laredo Petroleum, Inc. LPI 23.13%, up 23%.

In trading on Friday, utilities shares fell 1.3%.

Top Headline

Big Lots, Inc. BIG 9.58% reported better-than-expected earnings for its third quarter on Friday.

Big Lots posted quarterly earnings of $0.76 per share, surpassing analysts’ estimates of $0.66 per share. The company’s quarterly sales came in at $1.38 billion, also exceeding expectations of $1.35 billion. Its same-store sales climbed 17.8% year over year.

Equities Trading UP

Pioneer Power Solutions, Inc. PPSI 44.23% shares shot up 46% to $5.20 after the company announced a conclusive settlement with Myers Power Products.

Shares of Star Peak Energy Transition Corp. STPK 56.49% got a boost, shooting 57% to $15.82 after Stem, Inc. announced it will go public through a merger with Star Peak.

Sutro Biopharma, Inc. STRO 30.75% shares were also up, gaining 31% to $22.20 after the company reported announced updated data from its ongoing dose-escalation Phase 1 study of STRO-002, an antibody-drug conjugate, for patients with ovarian cancer, showing that out of the 31 evaluable patients, 10 patients met RECIST criteria.

Equities Trading DOWN

Yext, Inc. YEXT 16.07% shares tumbled 16% to $16.15 after the company issued weak Q4 sales guidance. DA Davidson maintained Yext with a Buy and lowered the price target from $22 to $20.5.

Shares of Cortexyme, Inc. CRTX 19.67% were down 19% to $38.81 as the company announced that the independent Data Monitoring Committee conducted a pre-planned interim analysis and recommended Cortexyme continue the Phase 2/3 GAIN trial of its Alzheimer's candidate atuzaginstat as planned to the 1-year endpoint. Top-line results are expected as planned in December 2021.

Precision BioSciences, Inc. DTIL 18.77% was down, falling 18% to $8.34 after reporting interim clinical results from its Phase 1/2a study of PBCAR0191.

Commodities

In commodity news, oil traded up 1.3% to $46.21, while gold traded down 0.1% to $1,840.70.

Silver traded up 0.6% Friday to $24.29 while copper rose 1% to $3.5260.

Euro zone

European shares closed higher today. The eurozone’s STOXX 600 rose 0.59%, the Spanish Ibex Index rose 1.49%, while Italy’s FTSE MIB Index rose 0.78%. Meanwhile, the German DAX 30 gained 0.35%, French CAC 40 rose 0.62% and London’s FTSE 100 gained 0.92%.

The Eurozone construction PMI increased to 45.6 in November versus 44.9 in the earlier month. The UK construction PMI climbed to 54.7 in November versus a five-month low reading of 53.1 in the prior month, while German construction PMI rose to 45.6 from 45.2.

Economics

The US economy added 245,000 jobs in November, versus a revised 610,000 in the prior month. The unemployment rate declined to 6.7% in November from 6.9% in the previous month.

The US trade deficit increased to $63.1 billion in October versus a revised $62.1 billion in the prior month. Imports to the US increased by $5.0 billion to $245.1 billion in October.

US factory orders increased 1% in October versus a revised 1.1% increase in the earlier month.

The total number of active U.S. oil rigs rose by 5 to 246 rigs this week, Baker Hughes Inc reported.

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.


RELATED CONTENT

Loading ...



Copyright © 2024 FOREXSTREET S.L., All rights reserved.